Informe de análisis de tamaño, participación y tendencias del mercado mundial de pruebas de infecciones virales transmitidas por artrópodos: descripción general de la industria y pronóstico hasta 2031

Análisis del mercado de pruebas de infecciones virales transmitidas por artrópodos

A medida que aumenta la incidencia mundial de estas infecciones debido a factores como el cambio climático, la urbanización y los viajes internacionales, ha aumentado la demanda de soluciones de prueba rápidas y precisas. El mercado cuenta con diversas herramientas de diagnóstico , incluidas pruebas moleculares, inmunoensayos y métodos culturales. Los avances recientes incluyen el desarrollo de pruebas moleculares más sensibles y portátiles. Además, las colaboraciones entre agencias de salud pública y empresas de diagnóstico tienen como objetivo mejorar las capacidades de respuesta global, lo que mejora el crecimiento del mercado.

Tamaño del mercado de pruebas de infecciones virales transmitidas por artrópodos

El tamaño del mercado mundial de pruebas de infecciones virales transmitidas por artrópodos se valoró en USD 1.14 mil millones en 2023 y se proyecta que alcance los USD 1.77 mil millones para 2031, con una CAGR del 5,65% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología de pacientes, análisis de canalización, análisis de precios y marco regulatorio.

Tendencias del mercado de pruebas de infecciones virales transmitidas por artrópodos

“ Innovaciones en tecnologías de diagnóstico”

Las innovaciones en tecnologías de diagnóstico, como las pruebas moleculares en el punto de atención y los inmunoensayos, están transformando el mercado al ofrecer una detección más rápida y precisa de estas infecciones. Una tendencia clave es el cambio hacia diagnósticos rápidos y portátiles, que permiten a los proveedores de atención médica diagnosticar rápidamente a los pacientes en áreas remotas o propensas a brotes. Estos avances están mejorando la detección temprana y el manejo de las infecciones virales, reduciendo la propagación de la enfermedad. A medida que aumentan las preocupaciones de salud pública mundial, la demanda de soluciones de prueba avanzadas y fáciles de usar continúa aumentando, lo que hace que este sea un área crítica de enfoque en el sector de diagnóstico de atención médica.

Alcance del informe y segmentación del mercado de pruebas de infecciones virales transmitidas por artrópodos

Arthropod-Borne Viral Infections Testing Market Definition

Arthropod-Borne Viral Infections Testing refers to the diagnostic processes used to detect viruses transmitted by arthropods, such as mosquitoes, ticks, and fleas. These viruses, including dengue, Zika, chikungunya, and West Nile, cause diseases that can lead to severe health complications. Testing methods include molecular tests, immunoassays, and culture-based approaches, which help in the timely identification and management of these infections to prevent outbreaks and ensure appropriate treatment.

Arthropod-Borne Viral Infections Testing Market Dynamics

Drivers

• Rising Prevalence of Arthropod-Borne Diseases

The increasing incidence of arthropod-borne diseases such as dengue, Zika, chikungunya, and West Nile virus significantly drives the demand for advanced testing solutions. These viral infections, transmitted primarily through mosquitoes, have seen a notable rise in global cases due to factors such as climate change, urbanization, and increased travel. For instance, dengue cases have surged dramatically in tropical and subtropical regions, prompting urgent healthcare responses. Consequently, there is a pressing need for efficient and reliable diagnostic methods to facilitate early detection and management of these diseases, ultimately enhancing patient outcomes and public health initiatives. This trend underscores the critical need for innovative testing solutions in the market.

• Advancements in Molecular Diagnostic Technologies

Advancements in molecular diagnostic technologies, including polymerase chain reaction (PCR) and next-generation sequencing (NGS), are pivotal in driving growth in the arthropod-borne viral infections testing market. These technologies allow for rapid and precise detection of viral pathogens, significantly enhancing diagnostic accuracy. PCR techniques can identify specific genetic material of viruses within hours, while NGS provides comprehensive genomic data, facilitating the understanding of viral mutations and epidemiology. As healthcare providers increasingly adopt these innovative testing solutions, they can respond more effectively to outbreaks and manage patient care, ultimately propelling the demand for molecular diagnostics in this critical sector of infectious disease testing.

Opportunities

• Telemedicine and Remote Testing Solutions

The rise of telemedicine and remote patient monitoring presents a significant opportunity for the arthropod-borne viral infections testing market, particularly through the development and distribution of at-home testing kits. These kits allow individuals in underserved regions to access diagnostic solutions conveniently, eliminating the barriers posed by distance and healthcare accessibility. As telehealth continues to grow, patients can conduct tests in the comfort of their homes and receive results quickly, facilitating timely medical intervention. This shift enhances patient engagement and reduces the burden on healthcare facilities, driving demand for innovative testing products tailored for remote use in the management of viral infections.

• Vaccine Development and Monitoring

The development of new vaccines for arthropod-borne diseases presents a significant market opportunity for specialized diagnostic solutions focused on efficacy and safety testing. As public health initiatives strive to combat viral infections such as dengue and Zika, the demand for comprehensive testing methods becomes essential to ensure vaccine performance and patient safety. Diagnostic tools that can accurately assess immune responses and identify adverse effects will be crucial in evaluating vaccine candidates during clinical trials and post-marketing surveillance. This need for rigorous testing supports vaccine development and fosters innovation in the diagnostics sector, driving growth and investment in cutting-edge testing technologies.

Restraints/Challenges

• High Cost of Molecular Diagnostic Technologies

The high costs associated with the development and implementation of advanced molecular diagnostic technologies, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), pose a significant challenge in the arthropod-borne viral infections testing market. These sophisticated technologies require substantial investment in equipment, reagents, and training, making them less accessible for smaller laboratories and healthcare providers, especially in low-resource settings. This financial barrier can lead to disparities in diagnostic capabilities, limiting timely and accurate testing in regions most affected by arthropod-borne diseases. Consequently, this challenge hampers effective disease management and control efforts, highlighting the need for more affordable and accessible testing solutions.

• Inconsistent Disease Surveillance

Variability in disease surveillance systems poses a significant restraint on the arthropod-borne viral infections testing market, as it can lead to incomplete and inconsistent data regarding infection prevalence. In many regions, particularly in low-resource settings, surveillance efforts may be underfunded or poorly organized, resulting in gaps in information about disease outbreaks and transmission patterns. This lack of reliable data can hinder effective public health responses, as decision-makers rely on accurate statistics to allocate resources and implement control measures. Consequently, the uncertainty in disease prevalence diminishes the perceived need for testing, negatively impacting market demand and stifling advancements in diagnostic capabilities.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Arthropod-Borne Viral Infections Testing Market Scope

The market is segmented on the basis of test type and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

• Molecular Tests
• Cultural Tests
• Immunoassays
• Others

End User

• Hospitals
• Research Centers
• Diagnostic Centers

Arthropod-Borne Viral Infections Testing Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, test type, and end-user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the arthropod-borne viral infections testing market, driven by the swift advancement of diagnostic technologies in the region. The integration of innovative solutions, such as PCR and next-generation sequencing, enhances testing accuracy and efficiency. Furthermore, robust healthcare infrastructure and substantial investment in research contribute to the region's leadership in this market.

The Asia-Pacific region is projected to experience substantial growth in the arthropod-borne viral infections testing market from 2024 to 2031, primarily due to its large population at risk for infections. The high prevalence of arboviruses in this area further exacerbates the demand for effective diagnostic solutions. Additionally, increasing public health awareness and improved healthcare infrastructure are likely to drive this market expansion in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Arthropod-Borne Viral Infections Testing Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Arthropod-Borne Viral Infections Testing Market Leaders Operating in the Market Are:

• Thermo Fisher Scientific, Inc. (U.S.)
• BioMérieux (France)
• Hologic, Inc. (U.S.)
• EUROIMMUN Medizinische Labordiagnostika AG (Germany)
• Bio-Rad Laboratories, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• InBios International Inc. (U.S.)
• Quest Diagnostics Incorporated (Estados Unidos)
• CERTEST BIOTEC (España)
• Respuesta Biomédica (Canadá)
• Chembio Diagnostics, Inc. (Estados Unidos)
• Abbott (Estados Unidos)

Últimos avances en el mercado de pruebas de infecciones virales transmitidas por artrópodos

• En mayo de 2024, el Fondo Global Health Innovative Technology (GHIT) anunció una inversión de aproximadamente 1.640 millones de yenes (10,8 millones de dólares) destinada a impulsar cuatro proyectos centrados en el desarrollo de nuevos tratamientos para la malaria y las enfermedades tropicales desatendidas. Esta iniciativa de financiación pone de relieve el compromiso de la organización de abordar los problemas sanitarios críticos en las regiones desatendidas. Al apoyar el desarrollo de fármacos innovadores, el GHIT pretende mejorar las opciones terapéuticas y los resultados sanitarios de las poblaciones afectadas en todo el mundo.
• En mayo de 2023, Astellas Pharma Inc. anunció su compromiso con el Fondo de Tecnología Innovadora para la Salud Mundial, cuyo objetivo es apoyar el desarrollo de medicamentos, herramientas de diagnóstico y vacunas destinadas a combatir diversas enfermedades infecciosas. Esta contribución se centra especialmente en enfermedades tropicales poco reconocidas que a menudo carecen de financiación y recursos suficientes. Al invertir en esta iniciativa, Astellas Pharma busca mejorar los resultados de salud mundial y abordar las brechas críticas en el manejo de las enfermedades infecciosas.
• En julio de 2022, Mylab Discovery Solutions presentó su innovador kit de análisis de enfermedades, el 'PathoDetect Extended Monsoon Fever Panel', que mostró una sensibilidad y especificidad impresionantes. Este panel avanzado diferencia eficazmente entre varias enfermedades infecciosas, entre ellas la malaria, la chikungunya, el dengue, el zika, la leptospirosis, las especies bacterianas de la salmonelosis y el parásito de la leishmaniasis. Con su capacidad para identificar con precisión múltiples patógenos, este kit de análisis mejora las capacidades de diagnóstico durante la temporada de monzones, abordando desafíos de salud críticos en las regiones afectadas.
• En noviembre de 2021, Achico, una empresa suiza de tecnología sanitaria, anunció el desarrollo de kits de diagnóstico específicos para el dengue. Estos innovadores kits de prueba aprovechan la plataforma de tecnología de aptámeros de ADN de la empresa, que ha demostrado ser eficaz para diagnosticar la COVID-19. Al aplicar esta tecnología avanzada al diagnóstico del dengue, Achico pretende mejorar la precisión y la eficiencia de las pruebas para esta importante enfermedad infecciosa.
• En noviembre de 2021, la empresa suiza de tecnología sanitaria Achico dio a conocer sus planes para desarrollar kits de diagnóstico para el dengue. Estos innovadores kits de prueba utilizarán la plataforma de tecnología de aptámeros de ADN de la empresa, que ya ha demostrado su eficacia en el diagnóstico de la COVID-19. Este avance tiene como objetivo mejorar las capacidades de diagnóstico del dengue, abordando la creciente necesidad de soluciones de prueba fiables.

SKU-63602